Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Treilleux

Showing results (151-160 of 186) with videos related to

Pageof 19
Sort By:
Breast Cancer Research and Treatment|June 30, 2010
Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancerFrançois Bertucci, Nathalie Borie, Henri Roche, et al.
Archives of Pathology & Laboratory Medicine|December 8, 2024
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?Amel Kime, Guillaume Bataillon, Isabelle Treilleux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trialLaetitia Collet, Maude Ardin, David Venet, et al.
Nature Medicine|April 8, 2025
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialOlivier Trédan, Damien Pouessel, Nicolas Penel, et al.
JAMA Network Open|April 9, 2024
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic AberrationsPhilip C Schouten, Sandra Schmidt, Kerstin Becker, et al.
Nature Communications|August 15, 2024
Targeting ERK-MYD88 interaction leads to ERK dysregulation and immunogenic cancer cell deathFrançois Virard, Stéphane Giraud, Mélanie Bonnet, et al.
Journal of Personalized Medicine|October 27, 2022
Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 TrialElise Bonnet, Véronique Haddad, Stanislas Quesada, et al.
Nature Communications|July 16, 2024
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trialIsabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, et al.
Nature Communications|January 6, 2026
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trialIsabelle Ray-Coquard, Marie-Christine Kaminsky-Forrett, Ryotaro Ohkuma, et al.
Medical Oncology (Northwood, London, England)|November 5, 2021
Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trialAlice Bonneville-Levard, Didier Frappaz, Olivier Tredan, et al.
Pageof 19

Showing results (151-160 of 186) with videos related to

Sort By:
Pageof 19
Breast Cancer Research and Treatment|June 30, 2010
Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancerFrançois Bertucci, Nathalie Borie, Henri Roche, et al.
Archives of Pathology & Laboratory Medicine|December 8, 2024
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?Amel Kime, Guillaume Bataillon, Isabelle Treilleux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trialLaetitia Collet, Maude Ardin, David Venet, et al.
Nature Medicine|April 8, 2025
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialOlivier Trédan, Damien Pouessel, Nicolas Penel, et al.
JAMA Network Open|April 9, 2024
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic AberrationsPhilip C Schouten, Sandra Schmidt, Kerstin Becker, et al.
Nature Communications|August 15, 2024
Targeting ERK-MYD88 interaction leads to ERK dysregulation and immunogenic cancer cell deathFrançois Virard, Stéphane Giraud, Mélanie Bonnet, et al.
Journal of Personalized Medicine|October 27, 2022
Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 TrialElise Bonnet, Véronique Haddad, Stanislas Quesada, et al.
Nature Communications|July 16, 2024
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trialIsabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, et al.
Nature Communications|January 6, 2026
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trialIsabelle Ray-Coquard, Marie-Christine Kaminsky-Forrett, Ryotaro Ohkuma, et al.
Medical Oncology (Northwood, London, England)|November 5, 2021
Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trialAlice Bonneville-Levard, Didier Frappaz, Olivier Tredan, et al.
Pageof 19